HC Wainwright keeps Buy on Centrus Energy with $300 price target
HC Wainwright reiterated its Buy rating on Centrus Energy with a $300 price target, implying 173% upside from the October 20 close of $109.88.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Analysts at HC Wainwright & Co. reiterated their Buy rating on Centrus Energy shares and kept a price target of $300. According to TradingView, citing Benzinga data, the target implies an upside of 173% from the October 20 close of $109.88.
The analysts estimate that Centrus Energy's revenue could rise from $489 million in 2026 to more than $5 billion by 2037. They attribute the growth to rising demand for uranium and separative work units (SWU), along with improving prices in both markets. They also said the recent acquisition of Westerman should strengthen the supply chain and broaden the customer base.
why it matters
For the uranium and enrichment market, this view points to expected long-term growth in demand and pricing. It is one brokerage's opinion rather than a confirmed forecast, so actual results will depend on demand and price trends. For energy investors, the note serves as a reference point for valuing the company.
tags
instruments
sources
- HC Wainwright & Co. reiterates Buy rating on SpyGlass Pharma, $37 price target — TradingView, 21 October 2026 at 11:50 UTC
- HC Wainwright & Co. reiterates Buy rating on Microbot Medical, $12 price target — TradingView, 21 October 2026 at 12:04 UTC
- HC Wainwright & Co. reiterates Buy rating on Centrus Energy, $300 price target — TradingView, 21 October 2026 at 12:11 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗